Polymeric Engineering of Aptamer-Drug Conjugates for Targeted Cancer Therapy.
Nucleic acid aptamers, also known as "chemical antibodies", have been widely employed in targeted cancer therapy and di-agnosis. For example, aptamer-drug conjugates (ApDCs) through covalent conjugation of cytotoxic warheads to aptamers, have demonstrated anticancer efficacy both in vitro and in vivo. However, a general strategy to endow ApDCs with enhanced biostability, prolonged circulation half-life, and high drug loading content remained elusive. Herein, we present a polymeric approach to engineer ApDCs via conjugation of cell-targeting aptamers with water-soluble polyprodrugs containing a reduc-tive environment-sensitive prodrug and biocompatible brush-like backbone. The resultant high-drug loading Ap-tamer-PolyproDrug Conjugates (ApPDCs) exhibited high nuclease resistance, extended in vivo circulation time, specific recognition and cellular uptake to target cells, reduction-triggered and fluorescent-reporting drug release, and effective cyto-toxicity. We could also further expand this design principle towards combination therapy by using two kinds of therapeutic drugs with distinct pharmacological mechanisms.